Introduction
The activation of antigen-specific CD4 + T cells relies on the capacity of antigen presenting cells (APCs) to internalise and present antigen, as peptide fragments, on MHC class II (MHC-II) molecules. Dendritic cells (DCs) are regarded as the most potent APC but B cells expressing a BCR specific for a particular antigen are also extremely proficient at capturing and presenting antigen to antigen-specific CD4 + T cells . This arises from the remarkable efficiency of the BCR in capturing a specific antigen and facilitating antigen delivery to MHC-II-rich compartments which specialise in the generation of MHC-II-peptide complexes . However, since BCRs are clonotypically produced within a large repertoire of B cells, it has been generally accepted that the majority of B cells play only a minor role in presenting antigen to T cells .
Recent reports have demonstrated that a number of cell types, including pheochromocytoma cell lines , DCs , T cells , natural killer cells and B cell lymphomas have the capacity to transfer membrane and cellular components. In the case of B cell lymphomas, membrane exchange is thought to be due to transfer of membrane components during direct cell contact and possibly via membrane nanotubes (also referred to as cytonemes) , in processes that are enhanced by BCR crosslinking. Since the most unique difference between antigen-specific B cells is their BCR, membrane exchange may allow the exquisite antigen binding and processing capacity of one B cell to be transferred to another via BCR transfer.
By this means it can be postulated that BCR transfer from antigen-specific B cells to bystander B cells during immune responses could enhance the capacity of the local B cell pool to specifically bind and present antigen, a process which may greatly enhance the development of CD4 + T cell responses. In the present study we examined the potential of B cells to exchange their BCRs and how this affects their capacity to present specific antigen.
Results

B cells share BCRs following activation
The demonstration of membrane exchange between B cell lymphomas upon BCR cross-linking suggests that BCRs may be transferred between B cells upon cell activation. To assess this possibility, we cultured splenocytes from hens egg lysozyme (HEL)-specific BCR- Figure S1A and S1B in Supporting Information). BCR transfer was found to be restricted to B cells as B220-negative cells acquired negligible amounts of donor IgM ( Figure   1B ).
BCR transfer is rapid, is not due to secreted Ig and is enhanced by specific antigen
The rate of BCR transfer between B cells was assessed by mixing whole cultures of LPS-activated MD4 and B6.CD45.1 splenocytes and determining IgM a transfer to B6.CD45.1 B cells over short periods of co-culture (Figure 2A ). At 37 o C substantial BCR transfer occurred within 10-20 min and by 60 min B6.CD45.1 B cells had gained ~60% of the IgM a levels that they had acquired after 3 days of continuous culture with MD4 splenocytes ( Figure   2A ). Similar IgM a transfer was observed with washed activated MD4 splenocytes, whereas low IgM a transfer was observed with the MD4 culture supernatant (CSN), this residual activity being completely depleted when CSN was passed through an 800nm filter ( Figure   2A ). Intriguingly, rapid BCR transfer also occurred after 1 hr incubation at 4 o C, conditions which normally inhibit endocytic and exocytic processes, including Ig secretion (Figure 2A ). Indeed, we have found that activated B cells from µ s -/-mice, which express surface IgM a but have essentially no capacity to secrete IgM a , have a similar capacity to transfer their BCRs relative to wild type IgM a secretors ( Figure 2B ). These results indicate that IgM transfer is not due to IgM secretion.
Freshly isolated B cells were unable to transfer their BCRs, whereas LPS-activated B cells could readily donate BCRs to both non-activated and activated B cells ( Figure 2C ), although only viable B cells mediated transfer ( Figure S2 ). Furthermore, the presence of specific antigen (HEL), but not an unrelated antigen (ovalbumin, (OVA)), substantially increased the transfer of HEL-specific IgM a to both LPS-activated and freshly isolated bystander B cells ( Figure 2D ). BCR transfer, therefore, appears to be dependent on donor B cell activation, does not require recipient B cell activation and can be further enhanced by BCR-specific antigen.
BCR donation to bystander B cells involves membrane transfer
It appears likely that BCR transfer is mediated by membrane donation. Consistent with this we observed that CD45.2 molecules and cell surface molecules covalently labelled with fluorescein were also transferred from MD4 cells to B6.CD45.1 B cells and those B cells that had acquired higher levels of these surface molecules were also the same B cells that gained higher levels of IgM a , suggesting co-transfer of the molecules ( Figure 3A) .
Furthermore, by labelling the activated MD4 B cells with the membrane intercalating dye, PKH-26, we could directly show membrane transfer in parallel with transfer of IgM a ( Figure   3B ). This was further enhanced by the addition of BCR-specific antigen over a wide concentration range ( Figure 3B ). These results suggest that membrane donation between B cells is responsible for BCR transfer. 
Discussion
In this report we describe a novel mechanism by which bystander B cells can acquire an antigen-specific BCRs from activated B cells and gain the ability to capture and present specific-foreign antigen, thereby increasing the effective APC pool. BCR transfer is mediated by direct membrane donation, demonstrating an important role for membrane transfer between antigen-specific and non-antigen-specific B cells during immune responses.
Recently, there have been several reports indicating that many cell types have the capacity to transfer membrane and cellular components as a form of intercellular communication ,
although the functional significance of this phenomenon is unclear. It should be noted, however, that DCs and B cells have been reported to acquire antigen tethered to cell surfaces and efficiently present these to antigen-specific T cells. In these cases, antigen could be acquired from multiple cell types but uptake appeared to be restricted to DCs or B cells bearing an antigen-specific BCR and hence appeared to be recipient, but not donor, driven as we have reported here. As with these reports, and despite our own extensive studies ( Figure   S4 ), the molecular basis of membrane exchange is uncertain. However, our confocal and electron microscopy studies suggest that plasma membranes from activated and bystander B cells may coalesce via short membranous extensions resembling short membrane nanotubes.
In this regard it should be noted that membrane nanotubes can transfer material between cells at temperatures as low as 0.7 o C and similarly BCR transfer occurs quite efficiently at 4 o C.
Furthermore, it has been reported that the formation of membrane nanotube-like extensions, referred to as cytonemes, are increased upon BCR stimulation , which in our study significantly enhances BCR transfer. The Rosa-EGFP Tg (EGFP-Tg) mice were generated by crossing a Rosa26 stop/flox-EGFP 
Cell preparation and purification
Leukocytes were obtained from spleen and/or lymph nodes as previously described .
Leukocyte subsets were purified by magnetic cell separation in LS columns (Miltenyi Biotec, Bergisch Gladbach, Germany) using streptavidin-conjugated MicroBeads (Miltenyi Biotec) to target biotin-conjugated mAb-labelled cells. CD4 + T cells were enriched from pooled lymph nodes as well as spleen, and B cells were enriched from spleen. The cells were incubated with biotin-conjugated mAbs (Pharmingen) specific for unwanted cell populations with mAbs used for CD4 + T cell enrichment being specific for CD8 (53-6.7), CD11b (M1/70), CD11c (HL3) and B220 (RA3-6B2) and with mAbs used for B cell enrichment being specific for CD4 (GK1.5), CD8 (53-6.7), CD11b (M1/70), CD11c (HL3) and CD90.2 (53-2.1). Negatively selected B cell and T cell populations were found to be 90-98% pure, as assessed by flow cytometry.
Fluorescent dye and covalent labelling of cells
Lymphocytes were labelled with the intracellular dye, 5-(and 6-) carboxfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) and were cell surface labelled with LC-N-hydroxysuccinimidyl-fluorescein (Pierce Rockford, IL), as previously described for CFSE labelling . PKH-26 (Sigma) labelling was performed according to the manufacturers instructions. The UV-excitable dye Hoechst 33258 (Calbiochem, La Jolla, CA) was used to discriminate between viable, dead and apoptotic cells . Cells (1-5x10 6 /ml) were labelled with 1 µg/ml of Hoechst 33258 for 7 min at 37 0 C prior to flow cytometry.
Preparation of HEL-OVA conjugates
Maleimide-activated OVA (Sigma) was conjugated to sulfhydrylated-HEL ( B6.CD45.1 hosts had received i.v. 3x10 7 RBC-depleted CFSE-labelled lymphocytes from OT-II lymph nodes and spleen 2 hr prior to MD4 adoptive transfer, to provide cognate T cell help. Spleen cells from host mice were harvested at various times, depleted of RBC by lysis and adjusted to 1-4x10 7 cell/ml, ready for antibody staining and flow cytometry. In some experiments animals were challenged i.v. with an additional bolus 10 µg of HEL 1 hr prior to spleen harvesting.
Antibody staining
Cells for flow cytometry analysis were stained on ice with specific mAbs and secondary fluorochrome conjugates as previously described . MAbs specific for CD4 
Confocal Microscopy
Confocal microscopy was performed with a Radiance Confocal Microscope (BioRad) using the Argon 488 nm laser as the source of excitation. For live cell imaging, 1x10 5 LPS activated MD4 splenic B cells, pre-labelled with PKH-26 and a Cy-Chrome-conjugated B220-specific mAb, were added to 5x10 5 Cy-Chrome-conjugated B220-specific mAblabelled LPS-activated EGFP-Tg splenic B cells on a cooling stage set at 4 0 C and images taken for 60 min. 
BCR transfer between B cells
In an attempt to define the molecular basis of BCR transfer a large number of inhibitors of cell adhesion, membrane integrity and membrane fusion were assessed for their ability to inhibit BCR donation to bystander cells. The culture system entailed mixing LPS-activated transgenic (MD4) B cells with freshly isolated splenic B cells and assessing BCR/membrane transfer after co-incubation for 2 hr at 37 o C. This system most closely mimics the in vivo situation where there is rapid unidirectional transfer of BCR from activated B cells to bystander naïve B cells.
A total of 26 mAbs or mAb combinations were examined for their ability to modify BCR transfer, mAbs being chosen that recognise cell surface molecules on B cells. Particular attention was given to investigating molecules that have been shown to be involved in cell adhesion and cell fusion (reviewed in Chen, E.H. & Olsen E.N., Science 308, [369] [370] [371] [372] [373] 2005) , with the same mAb clones being used that have been reported previously to block function. Also all mAbs were used at saturating concentrations. None of the mAbs tested inhibited BCR transfer, although a few mAbs significantly enhanced BCR transfer, namely anti-CD2, CD19, CD44, CD48 and CD62L. The effect of the CD19-specific mAb is not surprising as CD19 is a signalling molecule that can associate with the BCR and BCR engagement by antigen (HEL) also enhances transfer. CD2 and CD48 represent a receptor-ligand pair that may facilitate transfer, CD44 has been implicated in cell fusion whereas the role of CD62L requires further investigation. Metabolic inhibitors (sodium azide, 4 o C), protein kinase C inhibitors (Rottlerin, Gu6976), modifiers of plasma membrane lipid organization (annexin V, apolipoprotein-E, methyl β-cyclodextrin, CBZ-D-FFG, polyethleneglycol-lipid), cytoskeleton/microtubule disrupters (cytochalasin-B, latrunculin-B, colchicine), broad spectrum ion channel blockers (hexamethylamiloride, amantadine), gap junction blockers (1-octanol) and inhibition of protein secretion (Brefeldin A) had little or no effect on transfer. Soluble Nethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes, that facilitate intracellular membrane fusion, appeared to be not involved as Nethylmaleimide slightly enhanced rather than inhibited transfer. Fixation of the donor MD4 B cells with glutaraldehyde or paraformaldehyde prevented transfer. Schiff base formation has been reported to stabilise cell adhesion (Rhodes, J., Immunology Today 17, 436-39, 1996) but the continual presence of high concentrations (170 mM) of lysine, an inhibitor of Schiff base formation, actually enhanced BCR transfer. Freshly isolated CFSE-labelled MD4 spleen cells, together with 10 µg of HEL-OVA and 10 µg of LPS, were injected i.v. into B6.CD45.1 recipient mice 2 hr after the i.v. injection of CFSE-labelled OT-II lymphocytes. On day 4, animals were challenged iv with a 30 µg bolus of either HEL or HEL-OVA 1 hr prior to spleen harvest. Spleen cells were then labelled with IgM a , B220 and CD45.2 specific mAbs and B6.CD45.1 B cells (B220 + , CD45.2 -) sorted into populations expressing low levels (Low) and medium levels (Med) of IgM a by flow cytometry as indicated in the dot plot profile. Graded numbers of the different B cell populations, from both HEL and HEL-OVA challenged mice, were then assessed for their capacity to activate, (CD69 + and/or divided based on CFSE dilution), a constant number (1.5x10 5 ) of CFSE-labelled CD4 + OT-II lymphocytes after 3 days of co-incubation. Data are representative of 3 independent experiments.
